• Publications
  • Influence
Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes.
It is recognized that a chronic low-grade inflammation and an activation of the immune system are involved in the pathogenesis of obesity-related insulin resistance and type 2 diabetes. SystemicExpand
[Guidelines on cardiovascular disease prevention in clinical practice].
These recommandations are largely based on the "European Guidelines on Cardiovascular Disease Prevention in Clinical Practice" proposed by the "Third Joint Task Force of European and other SocietiesExpand
Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study
BACKGROUND In animal models, cannabinoid-1 receptor (CB1) blockade produces a lean phenotype, with resistance to diet-induced obesity and associated dyslipidaemia. We assessed the effect ofExpand
Roles of circadian rhythmicity and sleep in human glucose regulation.
I. Introduction II. Characteristics and Causal Mechanisms of 24-h Rhythms of Glucose Regulation in Normal Young Subjects A. 24-h variations in glucose tolerance B. Causal mechanisms III. AlterationsExpand
Clinical Pharmacokinetics of Metformin
  • A. Scheen
  • Medicine
  • Clinical pharmacokinetics
  • 1 May 1996
SummaryThe biguanide metformin (dimethylbiguanide) is an oral antihyperglycaemic agent widely used in the management of non-insulin-dependent diabetes mellitus (NIDDM). Considerable renewal ofExpand
Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study
BACKGROUND Rimonabant, a selective cannabinoid type 1 receptor blocker, reduces bodyweight and improves cardiovascular and metabolic risk factors in non-diabetic overweight or obese patients. The aimExpand
Pharmacokinetics of dipeptidylpeptidase‐4 inhibitors
  • A. Scheen
  • Medicine
  • Diabetes, obesity & metabolism
  • 1 August 2010
Type 2 diabetes (T2DM) is a complex disease combining defects in insulin secretion and insulin action. New compounds have been developed for improving glucose‐induced insulin secretion and glucoseExpand
Effect of valsartan on the incidence of diabetes and cardiovascular events.
BACKGROUND It is not known whether drugs that block the renin-angiotensin system reduce the risk of diabetes and cardiovascular events in patients with impaired glucose tolerance. METHODS In thisExpand
Effect of nateglinide on the incidence of diabetes and cardiovascular events.
BACKGROUND The ability of short-acting insulin secretagogues to reduce the risk of diabetes or cardiovascular events in people with impaired glucose tolerance is unknown. METHODS In a double-blind,Expand
Pharmacodynamics, Efficacy and Safety of Sodium–Glucose Co-Transporter Type 2 (SGLT2) Inhibitors for the Treatment of Type 2 Diabetes Mellitus
Inhibitors of sodium–glucose co-transporter type 2 (SGLT2) are proposed as a novel approach for the management of type 2 diabetes mellitus (T2DM). Several compounds are already available in manyExpand